Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.360 -0.100 (-4.07%)
Streaming Delayed Price Updated: 3:16 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 Next >
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
Via ACCESS Newswire
OKYO Pharma to Present at the Bio International Convention
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
From OKYO Pharma LTD
Via GlobeNewswire
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Chairman and CEO Acquire Shares
From OKYO Pharma LTD
Via GlobeNewswire
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Via ACCESS Newswire
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
From OKYO Pharma LTD
Via GlobeNewswire
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma CEO Interview to Air on Bloomberg TV
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.